REVEAL · 101MS408
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multicenter, open-label, randomized study evaluating the effects of natalizumab versus fingolimod on central nervous system tissue lesions and recovery in participants with active relapsing-remitting multiple sclerosis (REVEAL). EudraCT: 2013-004622-29.
Sponsor: BIOGEN
Phase: IV
Area: Neuroimmunology